Lesión oxidativa inducida por quimioterapia en la leucemia linfoblástica aguda pediátrica: El papel de la N-acetilcisteína (Revisión)

reduce treatment-related toxicity without consistently compromising antitumor efficacy, although outcomes appear to be dependent on timing, dosage and treatment context. While the favorable safety, low cost and accessibility of NAC support its potential clinical utility, current evidence remains limited, particularly in pediatric ALL populations. In conclusion, NAC represents a promising but context-dependent adjunctive strategy for mitigating chemotherapy-induced toxicity in pediatric ALL. Further well-designed clinical studies are required to define its optimal use, including timing, dosing and